Talmage D. Egan
No Rating Available
(Learn About Our Rating System)

Talmage D. Egan, MD

Languages spoken: English, Japanese

Clinical Locations

Primary Location

University of Utah Hospital

Anesthesiology
50 N Medical Dr
Salt Lake City , UT 84132
801-581-6393
Get Directions

Dr. Egan completed his undergraduate education at Brigham Young University, graduating Magna Cum Laude in the humanities. He attended medical school at the University of Utah School of Medicine where he was inducted into the Alpha Omega Alpha academic honor society. After completing a preliminary general surgery residency at the University of Utah, Dr. Egan sought postgraduate training in anesthesiology and critical care which he completed at Stanford University. Following residency he pursued fellowship training in clinical pharmacology also at Stanford. He recently completed intensive physician executive training at the Harvard School of Public Health.

Dr. Egan is currently staff physician and chair at the Department of Anesthesiology at the University of Utah Health Sciences Center. His clinical practice focuses on neurosurgery and obstetric patients. He is past President of the Medical Staff and Chairman of the Medical Board, and served for over a decade as the Chief of Neuroanesthesia.

Dr. Egan's research interests include the clinical pharmacology of sedatives and analgesics, the development of novel intravenous anesthetics and alternative propofol formulations, the development of optimal drug administration regimens based on pharmacokinetic-pharmacodynamic concepts, the identification of factors (i.e., gender, body weight, shock, SNPs, etc.) that influence drug behavior, and computer controlled drug delivery technology. These interests have resulted in successful entrepreneurial ventures, patents and trademarks. Dr. Egan is internationally regarded as a pioneer in the development of total intravenous anesthesia techniques, particularly the clinical application of the short acting opioid remifentanil, and the characterization of the interaction between propofol and opioids. His publications have been accompanied by numerous editorials and have been featured as cover stories in leading, peer-reviewed anesthesiology journals. Dr. Egan has mentored over 20 junior faculty and graduate students who have emerged as independent investigators.

Dr. Egan served for many years as a board member, treasurer, and president of the International Society for Anaesthetic Pharmacology. Currently an Associate Editor for the British Journal of Anaesthesia, he has also served as Associate Editor for Anesthesiology and guest reviewer for numerous other pharmacology, anesthesia and bioengineering journals. For many years Dr. Egan was a member and Chair of the American Society of Anesthesiology Subcommittee on Drug Disposition. He recently published a well-received anesthesia pharmacology and physiology textbook with Elsevier (Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application) as co-editor.

Dr. Egan was the inaugural recipient of the International Anesthesia Research Society’s Teaching Recognition Award. He is holder of the K.C. Wong Presidential Endowed Chair in Anesthesiology at the University of Utah. Dr. Egan has lectured extensively in the United States and internationally, including numerous honorary and keynote lectures at major universities and international anesthesiology societies.

His personal life is devoted to his wife of 30 years and their five children. He is fond of saying that his family is the most important element of his CV! Dr. Egan enjoys coaching basketball (two time Utah State AAU Boys Champions!), snow skiing, bass guitar, English literature and Japanese conversation.

Specialties

  • Obstetrical Anesthesia
  • Neuroanesthesia
  • Anesthesiology

Board Certification

American Board of Anesthesiology

Dr. Egan completed his undergraduate education at Brigham Young University, graduating Magna Cum Laude in the humanities. He attended medical school at the University of Utah School of Medicine where he was inducted into the Alpha Omega Alpha academic honor society. After completing a preliminary general surgery residency at the University of Utah, Dr. Egan sought postgraduate training in anesthesiology and critical care which he completed at Stanford University. Following residency he pursued fellowship training in clinical pharmacology also at Stanford. He recently completed intensive physician executive training at the Harvard School of Public Health.

Dr. Egan is currently staff physician and chair at the Department of Anesthesiology at the University of Utah Health Sciences Center. His clinical practice focuses on neurosurgery and obstetric patients. He is past President of the Medical Staff and Chairman of the Medical Board, and served for over a decade as the Chief of Neuroanesthesia.

Dr. Egan's research interests include the clinical pharmacology of sedatives and analgesics, the development of novel intravenous anesthetics and alternative propofol formulations, the development of optimal drug administration regimens based on pharmacokinetic-pharmacodynamic concepts, the identification of factors (i.e., gender, body weight, shock, SNPs, etc.) that influence drug behavior, and computer controlled drug delivery technology. These interests have resulted in successful entrepreneurial ventures, patents and trademarks. Dr. Egan is internationally regarded as a pioneer in the development of total intravenous anesthesia techniques, particularly the clinical application of the short acting opioid remifentanil, and the characterization of the interaction between propofol and opioids. His publications have been accompanied by numerous editorials and have been featured as cover stories in leading, peer-reviewed anesthesiology journals. Dr. Egan has mentored over 20 junior faculty and graduate students who have emerged as independent investigators.

Dr. Egan served for many years as a board member, treasurer, and president of the International Society for Anaesthetic Pharmacology. Currently an Associate Editor for the British Journal of Anaesthesia, he has also served as Associate Editor for Anesthesiology and guest reviewer for numerous other pharmacology, anesthesia and bioengineering journals. For many years Dr. Egan was a member and Chair of the American Society of Anesthesiology Subcommittee on Drug Disposition. He recently published a well-received anesthesia pharmacology and physiology textbook with Elsevier (Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application) as co-editor.

Dr. Egan was the inaugural recipient of the International Anesthesia Research Society’s Teaching Recognition Award. He is holder of the K.C. Wong Presidential Endowed Chair in Anesthesiology at the University of Utah. Dr. Egan has lectured extensively in the United States and internationally, including numerous honorary and keynote lectures at major universities and international anesthesiology societies.

His personal life is devoted to his wife of 30 years and their five children. He is fond of saying that his family is the most important element of his CV! Dr. Egan enjoys coaching basketball (two time Utah State AAU Boys Champions!), snow skiing, bass guitar, English literature and Japanese conversation.

Board Certification and Academic Information

Academic Departments Anesthesiology -Professor
Neurosurgery -Adjunct Professor
Board Certification
American Board of Anesthesiology

Education history

Undergraduate Humanities - Brigham Young University B.A.
Professional Medical Medicine - University of Utah M.D.
Internship Surgery - University of Utah School of Medicine Intern
Residency Surgery - University of Utah School of Medicine Resident
Residency Anesthesiology - University of Utah School of Medicine Resident
Residency Anesthesiology - Stanford University Medical Center Resident
Fellowship Pharmacology - Stanford University School of Medicine Fellow

Selected Publications

Journal Article

  1. Manullang J, Egan T (1999). Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency. Anesthesia and analgesia, 89(2), 529-30.
  2. Miner JE, Egan T (2000). An AIDS-associated cause of the difficult airway: supraglottic Kaposi's sarcoma. Anesthesia and analgesia, 90(5), 1223-6.
  3. Johnson KB, Swenson JD, Egan TD, Jarrett R, Johnson (2002). Midazolam and remifentanil by bolus injection for intensely stimulating procedures of brief duration: experience with awake laryngoscopy. Anesthesia and analgesia, 94(5), 1241-3, table of contents.
  4. Davis PJ, Stiller RL, Wilson AS, McGowan FX, Egan TD, Muir K (2002). In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesthesia and analgesia, 95(5), 1305-7, table of contents.
  5. Johnson KB, Egan TD, Layman J, Kern SE, White JL, McJames S (2003). The influence of hemorrhagic shock on etomidate: a pharmacokinetic and pharmacodynamic analysis. Anesthesia and analgesia, 96(5), 1360-8, table of contents.
  6. Egan TD, Kern SE, Johnson KB, Pace N (2003). The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesthesia and analgesia, 97(1), 72-9, table of contents.
  7. Davis JJ, Johnson KB, Egan TD, Vezina DP, Snell TE, Swenson J (2003). Preoperative fentanyl infusion with pharmacokinetic simulation for anesthetic and perioperative management of an opioid-tolerant patient. Anesthesia and analgesia, 97(6), 1661-2.
  8. Davis JJ, Swenson JD, Hall RH, Dillon JD, Johnson KB, Egan TD, Pace NL, Niu S (2005). Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. Anesthesia and analgesia, 101(2), 389-95, table of contents.
  9. Stanley TH, Egan TD, Van Aken (2008). A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesthesia and analgesia, 106(2), 451-62, table of contents.
  10. Johnson KB, Syroid ND, Gupta DK, Manyam SC, Egan TD, Huntington J, White JL, Tyler D, Westenskow D (2008). An evaluation of remifentanil propofol response surfaces for loss of responsiveness, loss of response to surrogates of painful stimuli and laryngoscopy in patients undergoing elective surgery. Anesthesia and analgesia, 106(2), 471-9, table of contents.
  11. Syroid ND, Johnson KB, Pace NL, Westenskow DR, Tyler D, Brühschwein F, Albert RW, Roalstad S, Costy-Bennett S, Egan T (2010). Response surface model predictions of emergence and response to pain in the recovery room: An evaluation of patients emerging from an isoflurane and fentanyl anesthetic. Anesthesia and analgesia, 111(2), 380-6.
  12. Johnson KB, Syroid ND, Gupta DK, Manyam SC, Pace NL, LaPierre CD, Egan TD, White JL, Tyler D, Westenskow D (2010). An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrations. Anesthesia and analgesia, 111(2), 387-94.
  13. LaPierre CD, Johnson KB, Randall BR, White JL, Egan T (2011). An exploration of remifentanil-propofol combinations that lead to a loss of response to esophageal instrumentation, a loss of responsiveness, and/or onset of intolerable ventilatory depression. Anesthesia and analgesia, 113(3), 490-9.
  14. Wallentine CB, Shimode N, Egan TD, Pace N (2011). Propofol in a modified cyclodextrin formulation: first human study of dose-response with emphasis on injection pain. Anesthesia and analgesia, 113(4), 738-41.
  15. Syroid N, Liu D, Albert R, Agutter J, Egan TD, Pace NL, Johnson KB, Dowdle MR, Pulsipher D, Westenskow D (2012). Graphical user interface simplifies infusion pump programming and enhances the ability to detect pump-related faults. Anesthesia and analgesia, 115(5), 1087-97.
  16. Egan T (1997). The clinical pharmacology of the new fentanyl congeners. Anesthesia and analgesia,
  17. Crystal B. Wallentine, MD, Noriko Shimode, MD, Talmage D. Egan, MD, and Nathan Pace, MD, MSta (2011). Propofol in a Modified Cyclodextrin Formulation: First Human Study of Dose-Response with Emphasis on Injection Pain. Anesthesia and analgesia, 113(4), 738-741.
  18. Shafer SL, Egan T (2016). Target-Controlled Infusions: Surfing USA Redux. Anesthesia and analgesia, 122(1), 1-3.
  19. Sear JW, Egan TD (2015). David (Propofol Wannabes) Versus Goliath (Propofol): AZD-3043 Goes Up Against the Giant!. Anesthesia and analgesia, 121(4), 849-51.
  20. Ermer S, Brewer L, Orr J, Egan TD, Johnson (2019). Comparison of 7 Different Sensors for Detecting Low Respiratory Rates Using a Single Breath Detection Algorithm in Nonintubated, Sedated Volunteers. Anesthesia and analgesia, 129(2), 399-408.
  21. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer S (1996). Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology, 84(4), 821-33.
  22. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer S (1997). Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology, 86(1), 10-23.
  23. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace N (1998). Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology, 88(2), 305-9.
  24. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir K (1998). Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology, 89(3), 562-73.
  25. Egan TD, Kuramkote S, Gong G, Zhang J, McJames SW, Bailey P (1999). Fentanyl pharmacokinetics in hemorrhagic shock: a porcine model. Anesthesiology, 91(1), 156-66.
  26. Egan TD, Sharma A, Ashburn MA, Kievit J, Pace NL, Streisand J (2000). Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology, 92(3), 665-73.
  27. Johnson KB, Kern SE, Hamber EA, McJames SW, Kohnstamm KM, Egan T (2001). Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 94(2), 322-32.
  28. Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer S (2001). Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology, 95(2), 324-33.
  29. Johnson KB, Egan TD, Kern SE, White JL, McJames SW, Syroid N, Whiddon D, Church (2003). The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 99(2), 409-20.
  30. Egan T (2003). Target-controlled drug delivery: progress toward an intravenous "vaporizer" and automated anesthetic administration. Anesthesiology, 99(5), 1214-9.
  31. Kern SE, Xie G, White JL, Egan T (2004). A response surface analysis of propofol-remifentanil pharmacodynamic interaction in volunteers. Anesthesiology, 100(6), 1373-81.
  32. Johnson KB, Egan TD, Kern SE, McJames SW, Cluff ML, Pace N (2004). Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 101(3), 647-59.
  33. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan T (2006). Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology, 105(2), 267-78.
  34. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan T (2007). When is a bispectral index of 60 too low?: Rational processed electroencephalographic targets are dependent on the sedative-opioid ratio. Anesthesiology, 106(3), 472-83.
  35. Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, Steffensen SC, Beattie D (2012). AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology, 116(6), 1267-77.
  36. LaPierre CD, Johnson KB, Randall BR, Egan T (2012). A simulation study of common propofol and propofol-opioid dosing regimens for upper endoscopy: implications on the time course of recovery. Anesthesiology, 117(2), 252-62.
  37. Yu L, Ting CK, Hill BE, Orr JA, Brewer LM, Johnson KB, Egan TD, Westenskow D (2013). Using the entropy of tracheal sounds to detect apnea during sedation in healthy nonobese volunteers. Anesthesiology, 118(6), 1341-9.
  38. Kim TK, Obara S, Egan TD, Minto CF, La Colla L, Drover DR, Vuyk J, Mertens M, the Remifentanil Pharmacokinetics in Obesity Investigators (2017). Disposition of Remifentanil in Obesity: A New Pharmacokinetic Model Incorporating the Influence of Body Mass. Anesthesiology, 126(6), 1019-1032.
  39. Kim TK, Obara S, Egan TD, Minto CF, La Colla L, Drover DR, Vuyk J, Mertens (2017). Disposition of Remifentanil in Obesity: A New Pharmacokinetic Model Incorporating the Influence of Body Mass. Anesthesiology, 126(6), 1019-1032.
  40. Egan T (2015). Total intravenous anesthesia versus inhalation anesthesia: a drug delivery perspective. Journal of cardiothoracic and vascular anesthesia, 29 Suppl 1, S3-6.
  41. Egan, T (2015). Total intravenous anesthesia versus inhalation anesthesia: a drug delivery perspective. Journal of cardiothoracic and vascular anesthesia, 29(Suppl 1), S3-6.
  42. Egan, T (2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. Journal of cardiothoracic and vascular anesthesia, 29(Suppl 1), S1-2.
  43. Egan T (1996). Intravenous drug delivery systems: toward an intravenous "vaporizer". Journal of clinical anesthesia, 8(3 Suppl), 8S-14S.
  44. Smyth E, Egan T (1998). Apneic oxygenation associated with patient-controlled analgesia. Journal of clinical anesthesia, 10(6), 499-501.
  45. Reusche MD, Egan T (1999). Remifentanil for conscious sedation and analgesia during awake fiberoptic tracheal intubation: a case report with pharmacokinetic simulations. Journal of clinical anesthesia, 11(1), 64-8.
  46. Nelson RY, Bretz B, Egan T (2007). Prolonged apnea after remifentanil. Journal of clinical anesthesia, 19, 60-63.
  47. Egan TD, Kern SE, Muir KT, White (2004). Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. British journal of anaesthesia, 92(3), 335-43.
  48. Kim TK, Niklewski PJ, Martin JF, Obara S, Egan T (2015). Enhancing a sedation score to include truly noxious stimulation: the Extended Observer's Assessment of Alertness and Sedation (EOAA/S). British journal of anaesthesia, 115(4), 569-77.
  49. Egan T (2019). Are opioids indispensable for general anaesthesia?. British journal of anaesthesia, 122(6), e127-e135.
  50. Johnson KB, Egan T (1998). Remifentanil and propofol combination for awake craniotomy: case report with pharmacokinetic simulations. Journal of neurosurgical anesthesiology, 10(1), 25-9.
  51. Manullang TR, Chun K, Egan T (2000). The use of remifentanil for Cesarean section in a parturient with recurrent aortic coarctation. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 47(5), 454-9.
  52. Hermann DJ, Egan TD, Muir K (1999). Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics, 65(5), 511-8.
  53. Lee M, Kern SE, Kisicki JC, Egan T (2003). A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. Journal of pain and symptom management, 26(2), 743-7.
  54. Egan T (1997). Remifentanil: an esterase-metabolized opioid. The Western journal of medicine, 166(3), 202.
  55. Coull JT, Jones ME, Egan TD, Frith CD, Maze (2004). Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. NeuroImage, 22(1), 315-22.
  56. Soto R, Jahr JS, Pavlin J, Sabo D, Philip BK, Egan TD, Rowe E, de Bie J, Woo (2016). Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial. American journal of therapeutics, 23(6), e1654-e1662.
  57. Farnsworth ST, Egan TD, Johnson SE, Westenskow (2000). Teaching sedation and analgesia with simulation. Journal of clinical monitoring and computing, 16(4), 273-85.
  58. Sakata DJ, Matsubara I, Gopalakrishnan NA, Westenskow DR, White JL, Yamamori S, Egan TD, Pace N (2009). Flow-through versus sidestream capnometry for detection of end tidal carbon dioxide in the sedated patient. Journal of clinical monitoring and computing, 23(2), 115-22.
  59. Sikharam S, Egan TD, Kern S (2005). Cyclodextrins as new formulation entities and therapeutic agents. Current opinion in anaesthesiology, 18(4), 392-5.
  60. Egan T (2000). Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000. Current opinion in anaesthesiology, 13(4), 449-55.
  61. Egan T (1998). The clinical pharmacology of remifentanil: a brief review. Journal of anesthesia, 12, 195-204.
  62. Richardson SP, Egan T (2005). The safety of remifentanil by bolus injection. Expert opinion on drug safety, 4(4), 643-51.
  63. Brada SA, Egan TD, Viscomi C (1998). The use of remifentanil infusion to facilitate epidural catheter placement in a parturient: a case report with pharmacokinetic simulations. International journal of obstetric anesthesia, 7(2), 124-7.
  64. Hanrahan SJ, Greger B, Parker RA, Ogura T, Obara S, Egan TD, House P (2013). The effects of propofol on local field potential spectra, action potential firing rate, and their temporal relationship in humans and felines. Frontiers in human neuroscience, 7, 136.
  65. Egan TD, Muir KT, Hermann DJ, Stanski DR, Shafer S (2001). The EEG and clinical measures of opioid potency: defining the EEG-clinical potency relationship ('fingerprint') with application to remifentanil. 15, 11-19.

Review

  1. Egan T (1998). The clinical pharmacology of remifentanil: a brief review. Journal of anesthesia, 12(4), 195-204.

Book

  1. Egan TD, Stanley T (1999). Anesthesia for the New Millenium: Modern Anesthetic Clinical Pharmacology.
  2. Hemmings HC, Egan T (2013). Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application.

Book Chapter

  1. Johnson KB, Egan T (2008). Principles of pharmacokinetics and pharmacodynamics: applied clinical pharmacology for the practitioner. Anesthesiology,
  2. Egan T (1999). Handedness in anesthetic pharmacology.
  3. Egan T (1997). Intravenous Drug Delivery Devices and Computer Control.
  4. Loose E, Egan T (2006). Short Acting Intravenous Anesthetics.
  5. Johnson KB, Egan T (2008). Blood loss: does it change my intravenous anesthetic?.
  6. Bailey PL, Egan T (1997). Fentanyl and Congeners.
  7. Egan TD, Wong K (1996). Cigarette Smoking Cessation and Anesthesia.
  8. Egan TD, Minto C (2003). Pharmacodynamic drug interactions in anesthetic practice.
  9. Egan TD, Wong K (2001). Cigarette Smoking Cessation and Anesthesia.
  10. Egan T (2001). Anesthetic considerations for awake craniotomy: a practical approach.
  11. Bailey PL, Egan TD, Stanley T (1999). Opioids.
  12. Egan T (1998). Modern clinical pharmacology concepts and pain management.
  13. Egan T (2001). The processed eletroencephalogram in clinical anesthesiology with special reference to the clinical application of the bisectral index.
  14. Egan T (1999). Remifentanil: clinical applications.
  15. Ladd AL, Egan TD, Swenson J (1999). Shoulder Surgery.
  16. Brody GA, Rinsky LA, Egan TD, Swenson J (1999). Hand Surgery.
  17. Thackeray E, Egan, T (2015). Analgesics.
  18. Obara S, Egan T (2013). Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics.
  19. Ogura T, Egan T (2013). Opioid Agonists and Antagonists. 253-271.
  20. Thackeray EM, Egan T (2015). Analgesics.
  21. Egan TD, Newberry (2018). Opioids.
  22. Johnson KB, Egan T (2015). Blood loss: Does it change my intravenous anesthetic?.

Case Report

  1. Honan DM, Breen PJ, Boylan JF, McDonald NJ, Egan T (2002). Decrease in bispectral index preceding intraoperative hemodynamic crisis: evidence of acute alteration of propofol pharmacokinetics. Anesthesiology, 97(5), 1303-5.
  2. Nelson RY, Bretz B, Egan T (2007). Prolonged apnea after remifentanil. Journal of clinical anesthesia, 19(1), 60-3.

Editorial

  1. Egan T (1996). Stereochemistry and anesthetic pharmacology: joining hands with the medicinal chemists. Anesthesia and analgesia, 83(3), 447-50.
  2. Sear JW, Egan T (2015). David (Propofol Wannabes) Versus Goliath (Propofol): AZD-3043 Goes Up Against the Giant!. Anesthesia and analgesia, 121(4), 849-51.
  3. Shafer SL, Egan T (2016). Target-controlled infusions: surfing USA redux. Anesthesia and analgesia, 122(1), 1-3.
  4. Egan TD, Svensen C (2018). Multimodal General Anesthesia: A Principled Approach to Producing the Drug-Induced, Reversible Coma of Anesthesia. Anesthesia and analgesia, 127(5), 1104-1106.
  5. Egan T (2018). An Intellectual Framework for Drug Administration Methods in Anesthesia: Three Practice Domains. Anesthesia and analgesia, 127(4), 817-819.
  6. Egan TD, Shafer S (2003). Target-controlled infusions for intravenous anesthetics: surfing USA not!. Anesthesiology, 99(5), 1039-41.
  7. Egan T (2009). Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology, 111(2), 229-30.
  8. Gupta DK, Manyam SC, Johnson KB, Egan T (2007). Can 1% of sevoflurane with 5 ng/ml of remifentanil prevent implicit memory?. Anesthesiology, 107, 1031.
  9. Egan T (2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. Journal of cardiothoracic and vascular anesthesia, 29 Suppl 1, S1-2.
  10. Egan, T (2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. Journal of cardiothoracic and vascular anesthesia, 29(Suppl 1), S1-2.
  11. Egan T (2010). Exploring the frontiers of propofol formulation strategy: is there life beyond the milky way?. British journal of anaesthesia, 104(5), 533-5.
  12. Kuck K, Egan T (2017). Getting the dose right: anaesthetic drug delivery and the posological sweet spot. British journal of anaesthesia, 119(5), 862-864.
  13. Short TG, Campbell D, Egan T (2018). Increasing the utility of target-controlled infusions: one model to rule them all. British journal of anaesthesia, 120(5), 887-890.
  14. Short TG, Campbell D, Egan T (2018). Increasing the utility of target-controlled infusions: one model to rule them all. 120(5), 887-890.
  15. Kuck K, Egan T (2017). Getting the dose right: anaesthetic drug delivery and the posological sweet spot. 119(5), 862-864.

Letter

  1. Egan T (1998). New horizons in IV anesthesia. Society for Intravenous Anesthesia Newsletter. Anesthesia and analgesia, 3 (1), 2.
  2. Bailey PL, Egan T (1997). The successful implementation of pharmaceutical practice guidelines? Far from convincing!. Anesthesiology, 87(6), 1583-4.
  3. Taikawa D, Soto E, Kurosaki D, Hiraoka H, Horiuchi R, Goto F, Johnson KB, Egan T (2005). Pharmacodynamics of propofol during hemorrhagic shock. Anesthesiology, 102(5), 1068-1070.
  4. Egan TD, Kern S (2004). Remifentanil is too potent to be given by bolus. British journal of anaesthesia, 93(2), 305-306.

Abstract

  1. Egan TD, Gupta SK, Sperry RJ, Yee JB, Huizinga B, Jaarsma RL, Muir K (1996). The pharmacokinetics of remifentanil in obese versus lean elective surgery patients. Anesthesia and analgesia, 82, S100.
  2. Manyam SC, Chatwin DM, Decou JA, Johnson KB, White TD, Egan T (2003). The auditory evoked potential and the bispectral index: A comparison study examining signal responses to inadequate anesthesia. Anesthesia and analgesia, 96, S132.
  3. Egan TD, Shafer SL, Jenkins TE, Beattie DT, Jaw-Tsai S (2003). The Pharmacokinetics and Pharmacodynamics of THRX-918661, a Novel Sedative/Hypnotic Agent. Anesthesiology, 99, A516.
  4. Egan TD, Kern SE, Johnson KB, Pace N (2002). The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesthesiology, 97, A437.
  5. Egan TD, Kern SE, White JL, Wells DL, Johnson J (1998). Assessing hypnotic and opioid interactions in volunteers using surrogate measures: a new study paradigm. Anesthesiology, A483.
  6. Kuramkote S, Egan TD, McJames S, Gong G, Bailey P (1997). Hemorrhagic shock alters fentanyl pharmacokinetics. Anesthesiology, 87, A374.
  7. Egan TD, Roland C, White JL, Gay MA, Kern S (2000). A pilot study of oral transmucosal etomidate in volunteers. Anesthesiology, 93, A519.
  8. Kern SE, Egan TD, White JL, Cluff (1999). Characterizing pharmacodynamic synergism between propofol and remifentanil in volunteers using response surfaces. Anesthesiology, 91, A342.
  9. Gupta DK, Manyam SC, Johnson KB, White JL, Egan T (2003). The Auditory Evoked Potential and the Bispectral Index: A Comparison of Signal Performance During Clinically Inadequate Anesthesia. Anesthesiology, 99, A328.
  10. Sakaguchi FH, Syroid ND, White JB, Tyler DL, Egan T (2003). Applying a Propofol-Remifentanil Response Surface Interaction Model in the Operating Room: An Observational Study. Anesthesiology, 99, A495.
  11. Johnson KB, Egan TD, McJames SW, Cluff ML, Kern S (2003). The Influence of Hemorrhagic Shock Followed by Crystalloid Resuscitation on Propofol: A Pharmacokinetic Analysis. Anesthesiology, 99, A652.
  12. Johnson KB, Peterson G, Egan TD, Kern SE, Pace N (2002). Does propofol influence its own pharmacokinetics? A look at short duration high does propofol infusions in swine. Anesthesiology, 97, A681.
  13. Lu J, Kern S, Schafer S, Bailey PL, Egan T (1997). Prospective pharmacokinetic and pharmacodynamic validation of the context sensitive half-time for alfentanil. Anesthesiology, 87, A347.
  14. Egan TD, Muir KT, Stanski DR, Shafer S (1996). The EEG versus clinical measures of opioid potency: defining the EEG-clinical potency fingerprint with application to remifentanil. Anesthesiology, 85, A349.
  15. Kern SE, Linares OJ, Egan T (2000). Non-linear indicators of electroencephalographic changes that correlate with changing anesthetic concentrations. Anesthesiology, 93, A1372.
  16. Kern SE, Dezaire DPJ, White JL, Egan T (1999). Assessing the facial EMB as an indicator of response to noxious stimuli in anesthetized volunteers. Anesthesiology, 91, A594.
  17. Johnson KJ, Kern SE, Egan T (1999). The effect of hypnotic-opioid interaction on target controlled infusion performance. Anesthesiology, 91, A343.
  18. Egan TD, Kern SE, White J (1999). Prospective pharmacokinetic and pharmacodynamic validation on propofol's context sensitive T 1/2. Anesthesiology, 91, A347.
  19. Kern SE, Johnson KB, Hamber EA, McJames S, Gong G, Kohnstamm K, Egan T (1998). The influence of hemorrhagic shock on remifentanil: a pharmacodynamic analysis. Anesthesiology, A523.
  20. Johnson KB, Kern SE, Hamber EA, McJames S, Gong G, Kohnstamm K, Egan T (1998). The influence of hemorrhagic shock on remifentanil: a pharmacokinetic analysis. Anesthesiology, A524.
  21. Egan TD, Kern SE, Johnson KB, Pace N (2001). The Pharmacodynamics of propofol in a modified cyclodextrin formulation versus propofol in an intralipid formulation: an electroencephalographic and hemodynamic study in a porcine model. Anesthesiology, 95, A490.
  22. Johnson KB, Egan TD, Kern SE, Whiddon D, Lee (2001). The influence of hemorrhagic shock on propofol: a pharmacokinetic analysis. Anesthesiology, 95, A649.
  23. Lertratanakul A, Kern SE, Egan T (2001). EEG Approximate Entropy for Assessment of Subject Responsiveness to Laryngoscopy. Anesthesiology, 95, A292.
  24. White JL, Kern SE, Egan T (1999). Analgesia and respiratory effects of remifentanil boluses in elderly and adult volunteers. Anesthesiology, 91, A14.
  25. Kern SE, Roland C, White JL, Gay MA, Egan T (2000). PK/PD Analysis of etomidate given across the buccal mucosa. Anesthesiology, 93, A532.
  26. Jones M, Coull J, Egan T, Maze (2001). Are subjects more easily aroused during sedation with the alpha-2 agonist dexmedetomidine?. British journal of anaesthesia, 86, 324P.
  27. Egan TD, Muir KT, Stanski DR, Shafer S (1996). Using the EEG fingerprint to define the clinical pharmacology of a new opioid: application to remifentanil. Clinical pharmacology and therapeutics, 59, 129.
  28. Mazer NA, Zobrist H, Stanworth SH, Egan T (2002). Oral transmucosal administration of fentanyl acutely lowers LH and testosterone levels in healthy young men.
  29. Egan TD, Kern SE, Roland CL, Gay (2001). The pharmacokinetics and safety of oral transmucosal fentanyl administered to healthy volunteers as two 400 mcg dosage units or as a single 800 mcg Actiq dosage unit.
  30. Egan TD, Kern SE, White JL, Cluff (2000). Characterizing pharmacodynamic synergism between propofol and remifentanil in volunteers using response surfaces.
  31. Brewer L, Enos JS, Orr JA, Egan TD, Johnson K (2017). A Computerized System to Prompt Healthy Volunteers to Breathe During Drug-Induced Respiratory Depression.
  32. Ermer S, Johnson KB, Orr JA, Hoehne S, White J, Egan TD, Brewer (2016). Analysis of Central and Obstructive Apnea Detection Using Combination Sensors.
  33. Ermer S, Brewer L, Orr JA, Egan TD, Johnson K (2018). Comparison of a Wide Respiratory Rate Range Reported from Seven Sensors in Non- Intubated, Spontaneously Breathing Volunteers.

Video/Film/CD/Web/Podcast

  1. Egan T (1997). The clinical pharmacology of the new fentanyl congeners. IARS Annual Meeting Review Course Lectures CD-ROM. International Anesthesia Research Society, Cleveland, OH.
  2. Egan, T (2004). Advances in depth of anesthesia monitoring technology: Audio Digest 2004;46(23): side A.
  3. KSL-TV Television Documentar (1998). Awake under the knife. Television documentary produced and broadcast by KSL-TV, a Salt Lake City, Utah based National Broadcasting Company affiliate, February 26th, 1998.
  4. Egan T (2001). Clinical pharmacology of opioids and sedative-hypnotics. Part of an entire issue entitled "Anesthesia for the Elderly." Audio Digest 2001; 43 (17): Track 14.
  5. Egan T (2007). Moderate sedation for non-anesthesiologists: the scientific basis of safe clinical practices. Medscape (www.medscape.com), released December 26, 2007.
  6. Egan T (1997). The New Fentanyl Congeners. Audio Digest 1997; 39(11): side A.
  7. Egan TD, Syroid N, Agutter J, Johnson K (2018). Safe Sedation Training for Moderate Sedation (SSTmoderate).
  8. Egan TD, Syroid N, Agutter J, Johnson K (2017). Safe Sedation Training for deep sedation (SSTdeep).

News & Podcasts

News